NZ595602A - Anti-cancer drugs, and uses relating for malignant melanoma and other cancers - Google Patents

Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Info

Publication number
NZ595602A
NZ595602A NZ595602A NZ59560210A NZ595602A NZ 595602 A NZ595602 A NZ 595602A NZ 595602 A NZ595602 A NZ 595602A NZ 59560210 A NZ59560210 A NZ 59560210A NZ 595602 A NZ595602 A NZ 595602A
Authority
NZ
New Zealand
Prior art keywords
cancers
malignant melanoma
cancer drugs
uses relating
dimethylamino
Prior art date
Application number
NZ595602A
Other languages
English (en)
Inventor
Ganga Raju Gokaraju
Sudhakar Kasina
Rama Raju Gokaraju
Venkata Kanaka Ranga Raju Gokaraju
Venkateswarlu Somepalli
Trimurtulu Golakoti
Kiran Bhupathiraju
Krishanu Sengupta
Venkata Krishna Raju Alluri
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of NZ595602A publication Critical patent/NZ595602A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/041,2,3-Triazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D517/00Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ595602A 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers NZ595602A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN959CH2009 2009-04-27
PCT/IN2010/000262 WO2010125575A1 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
NZ595602A true NZ595602A (en) 2013-05-31

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595602A NZ595602A (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Country Status (11)

Country Link
US (1) US8143237B2 (enExample)
EP (1) EP2424351B1 (enExample)
JP (1) JP5571168B2 (enExample)
KR (1) KR20120006554A (enExample)
CN (1) CN102438449B (enExample)
AU (1) AU2010243213B2 (enExample)
BR (1) BRPI1006651A2 (enExample)
CA (1) CA2759519A1 (enExample)
IL (1) IL215789A0 (enExample)
NZ (1) NZ595602A (enExample)
WO (1) WO2010125575A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
CN103906742A (zh) * 2011-09-28 2014-07-02 世宗大学校产学协力团 硒吩稠合芳族化合物和其制备方法
WO2014012074A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2016118951A2 (en) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도
WO2025005748A1 (ko) * 2023-06-29 2025-01-02 (주)아이젠사이언스 신규 셀레노펜 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
DE69724472T2 (de) * 1996-06-03 2004-06-17 Purdue Research Foundation, West Lafayette Selenophen-antitumormittel
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
WO2010029577A2 (en) * 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Also Published As

Publication number Publication date
CN102438449B (zh) 2014-06-18
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03
AU2010243213A1 (en) 2011-10-27
JP2012525329A (ja) 2012-10-22
US8143237B2 (en) 2012-03-27
CA2759519A1 (en) 2010-11-04
AU2010243213B2 (en) 2014-09-11
JP5571168B2 (ja) 2014-08-13
US20100272678A1 (en) 2010-10-28
KR20120006554A (ko) 2012-01-18
CN102438449A (zh) 2012-05-02
BRPI1006651A2 (pt) 2015-08-25
WO2010125575A1 (en) 2010-11-04
IL215789A0 (en) 2012-01-31
EP2424351B1 (en) 2015-10-21
HK1166591A1 (en) 2012-11-02

Similar Documents

Publication Publication Date Title
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
NZ577916A (en) Cyclopamine analogs
MX2014012695A (es) Derivados de isoindolona.
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
IL184872A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
IL185063A0 (en) Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX363609B (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
NZ594186A (en) Indole derivatives as anticancer agents
TN2011000627A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MY149716A (en) Pyridazine derivatives as smo inhibitors
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MY153921A (en) Aminopyrazole derivatives
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.
IN2012DN03182A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2023 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 26 APR 2030 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2020 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 APR 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140318